**American College of Radiology**
**ACR Appropriateness Criteria®**

**Clinical Condition:** Follow-up of Malignant or Aggressive Musculoskeletal Tumors

**Variant 1:** Lower-risk patient (low grade). Evaluation for metastatic disease to the lung from musculoskeletal primary. Baseline examination at time of diagnosis.

<table>
<thead>
<tr>
<th>Radiologic Procedure</th>
<th>Rating</th>
<th>Comments</th>
<th>RRL*</th>
</tr>
</thead>
<tbody>
<tr>
<td>CT chest without IV contrast</td>
<td>9</td>
<td>Despite some of the cost analysis studies, the panel believes early diagnosis of lung metastases is critical and that chest CT should be performed. If chest CT is done, chest x-ray is not necessary.</td>
<td>☢☢☢</td>
</tr>
<tr>
<td>FDG-PET/CT whole body</td>
<td>5</td>
<td>In individual cases, this procedure can be a good problem-solving tool. Outcomes data on FDG-PET/CT are pending. The CT portion of FDG-PET/CT, although unenhanced, can include thin-section images through the whole body, which can enhance diagnosis.</td>
<td>☢☢☢☢</td>
</tr>
<tr>
<td>X-ray chest</td>
<td>3</td>
<td></td>
<td>☢</td>
</tr>
<tr>
<td>CT chest with IV contrast</td>
<td>1</td>
<td></td>
<td>☢☢☢</td>
</tr>
<tr>
<td>CT chest without and with IV contrast</td>
<td>1</td>
<td></td>
<td>☢☢☢</td>
</tr>
</tbody>
</table>

*Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate*  
*Relative Radiation Level*

**Variant 2:** Lower-risk patient (low grade). Evaluation for metastatic disease to the lung from musculoskeletal primary. Follow-up examination 3–6 months after treatment or surgery.

<table>
<thead>
<tr>
<th>Radiologic Procedure</th>
<th>Rating</th>
<th>Comments</th>
<th>RRL*</th>
</tr>
</thead>
<tbody>
<tr>
<td>CT chest without IV contrast</td>
<td>9</td>
<td>Follow up every 3–6 months for 5 years. After 5 years, frequency can decrease to every 6–12 months.</td>
<td>☢☢☢</td>
</tr>
<tr>
<td>FDG-PET/CT whole body</td>
<td>4</td>
<td>This procedure can be a useful problem-solving tool if another study is equivocal.</td>
<td>☢☢☢☢</td>
</tr>
<tr>
<td>X-ray chest</td>
<td>3</td>
<td></td>
<td>☢</td>
</tr>
<tr>
<td>CT chest with IV contrast</td>
<td>1</td>
<td></td>
<td>☢☢☢</td>
</tr>
<tr>
<td>CT chest without and with IV contrast</td>
<td>1</td>
<td></td>
<td>☢☢☢</td>
</tr>
</tbody>
</table>

*Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate*  
*Relative Radiation Level*
**Clinical Condition:** Follow-up of Malignant or Aggressive Musculoskeletal Tumors

**Variant 3:** Higher-risk patient (high grade). Evaluation for metastatic disease to the lung from musculoskeletal primary. Baseline examination at time of diagnosis.

<table>
<thead>
<tr>
<th>Radiologic Procedure</th>
<th>Rating</th>
<th>Comments</th>
<th>RRL*</th>
</tr>
</thead>
<tbody>
<tr>
<td>CT chest without IV contrast</td>
<td>9</td>
<td>Despite some of the cost analysis studies, the panel believes early diagnosis of lung metastases is critical and that chest CT should be performed. If chest CT is done, chest x-ray is not necessary.</td>
<td>☢☢☢</td>
</tr>
<tr>
<td>FDG-PET/CT whole body</td>
<td>7</td>
<td>In individual cases, this procedure can be a good problem-solving tool. FDG-PET/CT also appears to be emerging as a primary diagnostic tool for diagnosing metastatic disease in many musculoskeletal tumors.</td>
<td>☢☢☢☢</td>
</tr>
<tr>
<td>X-ray chest</td>
<td>2</td>
<td>☢</td>
<td></td>
</tr>
<tr>
<td>CT chest with IV contrast</td>
<td>1</td>
<td>☢☢☢</td>
<td></td>
</tr>
<tr>
<td>CT chest without and with IV contrast</td>
<td>1</td>
<td>☢☢☢</td>
<td></td>
</tr>
</tbody>
</table>

**Rating Scale:** 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate

*Relative Radiation Level

**Variant 4:** Higher-risk patient (high grade). Evaluation for metastatic disease to the lung from musculoskeletal primary. Follow-up examination 3–6 months after treatment or surgery.

<table>
<thead>
<tr>
<th>Radiologic Procedure</th>
<th>Rating</th>
<th>Comments</th>
<th>RRL*</th>
</tr>
</thead>
<tbody>
<tr>
<td>CT chest without IV contrast</td>
<td>9</td>
<td>☢☢☢</td>
<td></td>
</tr>
<tr>
<td>FDG-PET/CT whole body</td>
<td>5</td>
<td>This procedure can be a useful problem-solving tool if another study is equivocal.</td>
<td>☢☢☢☢</td>
</tr>
<tr>
<td>X-ray chest</td>
<td>2</td>
<td>☢</td>
<td></td>
</tr>
<tr>
<td>CT chest with IV contrast</td>
<td>1</td>
<td>☢☢☢</td>
<td></td>
</tr>
<tr>
<td>CT chest without and with IV contrast</td>
<td>1</td>
<td>☢☢☢</td>
<td></td>
</tr>
</tbody>
</table>

**Rating Scale:** 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate

*Relative Radiation Level
**Clinical Condition:** Follow-up of Malignant or Aggressive Musculoskeletal Tumors

**Variant 5:** Evaluation for osseous metastatic disease from musculoskeletal primary. Asymptomatic. Baseline and follow-up examination.

<table>
<thead>
<tr>
<th>Radiologic Procedure</th>
<th>Rating</th>
<th>Comments</th>
<th>RRL*</th>
</tr>
</thead>
<tbody>
<tr>
<td>FDG-PET/CT whole body</td>
<td>2</td>
<td>Although additional imaging should be provided only if the patient is symptomatic, it should be noted that in many cases, baseline whole-body FDG-PET/CT or MRI would already have been done, which provides high sensitivity for some bone tumors.</td>
<td>☢☢☢☢</td>
</tr>
<tr>
<td>Bone scan whole body</td>
<td>2</td>
<td></td>
<td>☢☢</td>
</tr>
<tr>
<td>MRI whole body without IV contrast</td>
<td>2</td>
<td></td>
<td>O</td>
</tr>
<tr>
<td>MRI whole body without and with IV contrast</td>
<td>2</td>
<td></td>
<td>O</td>
</tr>
</tbody>
</table>

*Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate

**Variant 6:** Evaluation for osseous metastatic disease from musculoskeletal primary. Symptomatic. Baseline and follow-up examination.

<table>
<thead>
<tr>
<th>Radiologic Procedure</th>
<th>Rating</th>
<th>Comments</th>
<th>RRL*</th>
</tr>
</thead>
<tbody>
<tr>
<td>FDG-PET/CT whole body</td>
<td>7</td>
<td>In individual cases, this procedure can be a good problem-solving tool. Sclerotic lesions are more difficult to detect with PET but are well demonstrated on the CT portion of the FDG-PET/CT examination.</td>
<td>☢☢☢☢</td>
</tr>
<tr>
<td>Bone scan whole body</td>
<td>5</td>
<td>Useful screening tool. In cases of abnormal spine uptake, SPECT/CT can be used to better distinguish metastases from degenerative changes.</td>
<td>☢☢</td>
</tr>
<tr>
<td>MRI whole body without IV contrast</td>
<td>5</td>
<td>This procedure has demonstrated superior sensitivity and diagnostic accuracy compared to FDG-PET/CT. The value of this modality must be balanced against the time necessary to accomplish the study and the inconsistent availability of the expertise needed to interpret it.</td>
<td>O</td>
</tr>
<tr>
<td>MRI whole body without and with IV contrast</td>
<td>1</td>
<td></td>
<td>O</td>
</tr>
</tbody>
</table>

*Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate

---

ACR Appropriateness Criteria®  
Follow-up Musculoskeletal Tumors
Clinical Condition: Follow-up of Malignant or Aggressive Musculoskeletal Tumors

**Variant 7:** Osseous tumor, without significant hardware present. Local recurrence.

<table>
<thead>
<tr>
<th>Radiologic Procedure</th>
<th>Rating</th>
<th>Comments</th>
<th>RRL*</th>
</tr>
</thead>
<tbody>
<tr>
<td>X-ray area of interest</td>
<td>9</td>
<td>Both MRI and x-ray are indicated.</td>
<td>Varies</td>
</tr>
<tr>
<td>MRI area of interest without and with IV contrast</td>
<td>9</td>
<td>Both MRI and x-ray are indicated. Contrast administration is helpful for further evaluation of equivocal findings.</td>
<td>O</td>
</tr>
<tr>
<td>MRI area of interest without IV contrast</td>
<td>8</td>
<td>Both MRI and x-ray are indicated.</td>
<td>O</td>
</tr>
<tr>
<td>FDG-PET/CT whole body</td>
<td>4</td>
<td>This procedure can be a useful problem-solving tool if another study is equivocal.</td>
<td></td>
</tr>
<tr>
<td>CT area of interest without IV contrast</td>
<td>4</td>
<td>On a case-by-case basis, CT can be useful. This procedure is useful for osseous tumors when better definition of bony anatomy is needed.</td>
<td>Varies</td>
</tr>
<tr>
<td>CT area of interest without and with IV contrast</td>
<td>4</td>
<td>Varies</td>
<td></td>
</tr>
<tr>
<td>CT area of interest with IV contrast</td>
<td>3</td>
<td>Varies</td>
<td></td>
</tr>
<tr>
<td>US area of interest</td>
<td>1</td>
<td></td>
<td>O</td>
</tr>
</tbody>
</table>

**Rating Scale:** 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate

**Rating Level:**

---

**Variant 8:** Osseous tumor, with significant hardware present. Local recurrence.

<table>
<thead>
<tr>
<th>Radiologic Procedure</th>
<th>Rating</th>
<th>Comments</th>
<th>RRL*</th>
</tr>
</thead>
<tbody>
<tr>
<td>X-ray area of interest</td>
<td>9</td>
<td></td>
<td>Varies</td>
</tr>
<tr>
<td>MRI area of interest without IV contrast</td>
<td>7</td>
<td>Metal suppression techniques can be used.</td>
<td>O</td>
</tr>
<tr>
<td>MRI area of interest without and with IV contrast</td>
<td>7</td>
<td>Metal suppression techniques can be used. Contrast administration is helpful for further evaluation of equivocal findings. Since fat suppression is inhomogeneous with adjacent hardware, pre- and postcontrast subtraction postprocessing is recommended.</td>
<td>O</td>
</tr>
<tr>
<td>FDG-PET/CT whole body</td>
<td>5</td>
<td>This procedure can be a useful problem-solving tool if another study is equivocal.</td>
<td></td>
</tr>
<tr>
<td>CT area of interest without IV contrast</td>
<td>5</td>
<td>This procedure can be useful if MRI is not informative. Alter technique to decrease metal artifact.</td>
<td>Varies</td>
</tr>
<tr>
<td>CT area of interest with IV contrast</td>
<td>5</td>
<td>Varies</td>
<td></td>
</tr>
<tr>
<td>CT area of interest without and with IV contrast</td>
<td>2</td>
<td>Varies</td>
<td></td>
</tr>
<tr>
<td>US area of interest</td>
<td>2</td>
<td></td>
<td>O</td>
</tr>
</tbody>
</table>

**Rating Scale:** 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate

**Rating Level:**

---
Clinical Condition: Follow-up of Malignant or Aggressive Musculoskeletal Tumors

Variant 9: Soft-tissue tumors. Local recurrence surveillance. Follow-up examination 3–6 months after treatment or surgery.

<table>
<thead>
<tr>
<th>Radiologic Procedure</th>
<th>Rating</th>
<th>Comments</th>
<th>RRL*</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRI area of interest without and with IV contrast</td>
<td>9</td>
<td>Contrast administration is helpful for further evaluation of equivocal findings. Follow-up every 3–6 months for 5 years. After 5 years, frequency can decrease to every 12 months, or the follow-up can be performed earlier if symptomatic.</td>
<td>O</td>
</tr>
<tr>
<td>MRI area of interest without IV contrast</td>
<td>8</td>
<td></td>
<td>O</td>
</tr>
<tr>
<td>FDG-PET/CT whole body</td>
<td>6</td>
<td>This procedure can be a useful problem-solving tool if another study is equivocal. Outcomes data on FDG-PET/CT are pending. The CT portion of FDG-PET/CT includes thin-section images through the whole body, which can enhance diagnosis.</td>
<td>☢☢☢☢</td>
</tr>
<tr>
<td>CT area of interest with IV contrast</td>
<td>5</td>
<td></td>
<td>Varies</td>
</tr>
<tr>
<td>US area of interest</td>
<td>5</td>
<td></td>
<td>O</td>
</tr>
<tr>
<td>X-ray area of interest</td>
<td>2</td>
<td>This procedure can be a problem-solver if needed to interpret findings on MRI.</td>
<td>Varies</td>
</tr>
<tr>
<td>CT area of interest without IV contrast</td>
<td>2</td>
<td>Postoperative scarring can obscure local recurrence.</td>
<td>Varies</td>
</tr>
<tr>
<td>CT area of interest without and with IV contrast</td>
<td>2</td>
<td></td>
<td>Varies</td>
</tr>
</tbody>
</table>

Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate

*Relative Radiation Level
FOLLOW-UP OF MALIGNANT OR AGGRESSIVE MUSCULOSKELETAL TUMORS

Expert Panel on Musculoskeletal Imaging: Catherine C. Roberts, MD1; Mark J. Kransdorf, MD2; Francesca D. Beaman, MD3; Ronald S. Adler, MD, PhD4; Behrang Amini, MD, PhD5; Marc Appel, MD6; Stephanie A. Bernard, MD7; Ian Blair Fries, MD8; Isabelle M. Germano, MD9; Bennett S. Greenspan, MD, MS10; Langston T. Holly, MD11; Charlotte D. Kubicky, MD, PhD12; Simon Shek-Man Lo, MB, ChB13; Timothy J. Mosher, MD14; Andrew E. Sloan, MD15; Michael J. Tuite, MD16; Eric A. Walker, MD17; Robert J. Ward, MD18; Daniel E. Wessell, MD19; Barbara N. Weissman, MD.20

Summary of Literature Review

Introduction/Background

This topic specifically excludes 1) metastatic disease from nonmusculoskeletal primaries, 2) head and neck tumors, 3) spine tumors, 4) chest wall tumors, 5) multiple myeloma, and 6) benign or nonaggressive bone or soft-tissue tumors. Evaluation for chemotherapy or radiation therapy effectiveness, preoperatively after induction therapy, is also not included.

It should be noted that there are no controlled studies in the literature that directly address the issue of tumor follow-up, and the recommendations here are based on consensus of the ACR Appropriateness Criteria Expert Panel on Musculoskeletal Imaging, are subject to change if new data come out, and should be used only as a guideline, with generous opportunity for modification in individual circumstances.

This topic addresses 2 issues regarding follow-up for tumor therapy: the timing of the follow-up examination and the type of imaging best used.

Ideally, the timing of follow-up for tumor recurrence or metastatic disease would be individualized for each tumor type and each patient. To design a follow-up protocol, one would generally wish to know the following: 1) How good is the imaging test to be used for detecting the presence of tumor, 2) How important is early detection of relapse in relation to salvage effectiveness (utility/risk analysis), and 3) When is the relapse most likely to occur (hazard rate). Individual hazard rate is related to tumor type, grade, size, and central location; patient age and gender; tumor stage; type of treatment; and surgical margins. Overall, the goal of an imaging protocol is to concentrate testing when the relapse is most likely to occur. This presumes that testing frequency should gradually decrease over time. There are outstanding reviews of model development for such protocols in lymphoma and other tumors [1-3]. However, such models do not exist for individual extremity tumors.

Because models relating to the hazard rate and utility/risk analysis do not exist for individual extremity bone and soft-tissue tumor types, we will consider the sarcomas as a group and try to evaluate general local recurrence rate and timing as well as metastatic rate and timing. The most helpful general information can be found in previously published practice guidelines [4-6]. The information most commonly agreed to among these authors is that approximately 80% of high-risk patients who recur locally or systemically will do so within 2–3 years of their primary treatment. This suggests that the most aggressive follow-up should occur in the first 2 years, with tapering of imaging after that time. The risk of relapse never drops to zero, so lifetime surveillance is warranted [4-7].

Overview

The incidence of metastatic disease from sarcomas varies considerably in large studies and is dependent on length of follow-up. Metastatic disease only to the lung involves about a third of patients [8-10]. In one study of

---

1Principal author, Mayo Clinic, Phoenix, Arizona. 2Panel Chair, Mayo Clinic, Phoenix, Arizona. 3Panel Vice-chair, University of Kentucky, Lexington, Kentucky. 4NYU Center for Musculoskeletal Care, New York, New York. 5University of Texas MD Anderson Cancer Center, Houston, Texas. 6Warwick Valley Orthopedic Surgery, Warwick, New York, American Academy of Orthopaedic Surgeons. 7Penn State University Milton S. Hershey Medical Center, Hershey, Pennsylvania. 8Bone, Spine and Hand Surgery, Chartered, Brick, NJ. American Academy of Orthopaedic Surgeons. 9Mount Sinai School of Medicine, New York, New York, neurosurgical consultant. 10Medical College of Georgia, Augusta, Georgia. 11University of California Los Angeles Medical Center, Los Angeles, California, neurosurgical consultant. 12Oregon Health & Science University, Portland, Oregon. 13University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio. 14Penn State University Milton S. Hershey Medical Center, Hershey, Pennsylvania. 15University Hospital Case Medical Center, Cleveland, Ohio, neurosurgical consultant. 16University of Wisconsin Hospital, Madison, Wisconsin. 17Penn State University Milton S. Hershey Medical Center, Hershey, Pennsylvania. 18Tufts Medical Center, Boston, Massachusetts. 19Mayo Clinic, Jacksonville, Florida. 20Specialty Chair, Brigham & Women’s Hospital, Boston, Massachusetts.

The American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through society representation on expert panels. Participation by representatives from collaborating societies on the expert panel does not necessarily imply individual or society endorsement of the final document.

Reprint requests to: publications@acr.org

ACR Appropriateness Criteria®

6 Follow-up Musculoskeletal Tumors
extremity soft-tissue sarcomas, there was no significant difference in distant metastases or death from disease in patients who either did or did not have a local recurrence [11]. In at least some of these studies, it appears as though the incidence of local recurrence is less frequent than the occurrence of metastatic disease in high-grade sarcomas, although the adequacy of local therapy is one of the crucial factors determining durable local tumor control [12,13]. Therefore, local failure may not be the initiating factor in systemic metastases. This finding suggests that follow-up studies should include systemic surveillance as well as imaging for local recurrence. Although the prognosis for patients with metastatic disease is poor, surveillance is warranted because early detection and treatment of locally recurrent and metastatic disease can prolong survival [8,14-16].

The specific type of imaging for follow-up to check for local recurrence will depend on the site of the original tumor (osseous versus soft tissue) as well as the type of therapy used (including curettage with bone graft versus resection with allograft versus soft-tissue resection, all taking into account the presence or absence of hardware). The following comments relate to each of these situations.

Discussion of Imaging Modalities by Variant

Variants 1, 2, 3, and 4: Metastatic Disease to Lung in Lower-Risk and Higher-Risk Patients

Of the systemic metastases, lung metastasis is by far the most frequent. It is generally accepted that computed tomography (CT) is more accurate for diagnosing lung parenchymal metastatic disease than is chest radiography. However, that increased accuracy may not translate to a positive cost-benefit analysis. One study retrospectively assigned patients to a low- or high-risk theoretical protocol. The incremental cost-effectiveness ratio was $731,000 for routine chest CT imaging to detect each additional case of metastatic disease [17]. Based on this finding, those authors recommend reserving CT selectively for high-risk patients. It has also been suggested that CT be used to follow nodules that are not visible on radiographs and for surgical planning of metastasectomy [18]. Another study favored the use of CT due to increased survival in patients undergoing pulmonary metastatic disease surveillance with CT compared with chest radiography [19]. Given the higher accuracy of CT, as well as the fact that pulmonary metastases from sarcomas are frequently cured by surgical excision [15] or radiofrequency ablation [20], it is likely that the use of CT for staging and surveillance for lung metastases will continue.

In terms of frequency of follow-up, some experts recommend that high-risk patients have follow-up every 3–4 months for the first 2–3 years, then every 6 months for up to 5 years, and then annually. Patients with low-grade sarcomas should have follow-up every 4–6 months for 3–5 years and then annually afterward [4,6]. Recommendations from the National Comprehensive Care Network for soft-tissue sarcomas are based on the stage of the tumor [5]. Stage I sarcomas receive chest imaging every 6 to 12 months for 2–3 years. Stage II–IV sarcomas receive chest imaging every 3–6 months for 2–3 years and then annually thereafter. The optimal frequency and modality of follow-up imaging have not been scientifically established.

Variants 5 and 6: Osseous Metastases from Musculoskeletal Primary

The frequency of distant metastatic disease, other than to lung, ranges from 14% to 20%. It is debatable whether surveillance for osseous metastases or lymphatic metastatic disease is cost efficient. If required, technetium bone scan or PET/CT is most frequently used. Where available, whole-body magnetic resonance imaging (WB-MRI) can detect osseous metastases with good sensitivity and high specificity [21-23]. Opposed-phase gradient-echo sequences are useful to improve specificity when equivocal marrow changes are seen on MRI [24-26].

The use of fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET)/CT has been shown to be effective in localizing metastases from many bone sarcomas, though it may be nonspecific and produces false negatives in osteosarcoma bone metastases [27,28]. Although bone scan, FDG-PET/CT, and MRI may detect osseous metastases, these studies are generally not advocated as part of the initial workup or follow-up for osseous metastases in asymptomatic cases.

With regard to screening for osseous metastases, Schmidt et al [23] showed that coronal whole-body and sagittal spine MRI using T1-weighted and short tau inversion recovery sequences was superior to FDG-PET/CT in sensitivity and diagnostic accuracy. Costelloe et al [21] found that fast Dixon WB-MRI had 89% specificity and was more sensitive than bone scan for detecting bone metastasis. A meta-analysis showed WB-MRI to have a pooled sensitivity of 89.9% and specificity of 91.8%. They also found WB-MRI to be cost effective. Thus, in centers that have the capability to do WB-MRI, this is a good alternative to FDG-PET/CT or bone scan and has the added benefit of lacking ionizing radiation exposure.
There is a paucity of recent literature regarding whole-body bone scan and screening for osseous metastases. Much of this likely relates to recent advances in FDG-PET/CT and WB-MRI and their superior anatomic resolution and specificity. Nonetheless, whole-body bone scan remains a useful screening tool in osseous metastatic disease, with an overall sensitivity comparable to that of FDG-PET/CT [29]. In cases where there is abnormal radiotracer uptake in the spine, single-photon emission computed tomography (SPECT)/CT can be used to better distinguish metastases from degenerative changes, thus increasing specificity [30].

Metastatic disease from primary extremity liposarcoma deserves special note. A retrospective study of 45 patients with myxoid liposarcoma found that all metastases were extrapulmonary, with the spine and paraspinal soft tissues being most commonly involved [31]. This study also reports a local recurrence at 7.7 years postoperative and new metastatic disease occurring over 10 years postoperative. Thus, a biopsy-proven primary myxoid liposarcoma in the trunk or retroperitoneum should prompt a rigorous search for an occult extremity primary. A subsequent prospective study following 230 patients with myxoid liposarcoma showed that the great majority of patients who developed metastatic disease had a bone metastasis as their first metastatic focus. Of these, the vast majority of the metastases were in the spine [32]. Thus, it seems reasonable that screening MRI of the spine be performed in patients newly diagnosed with or being followed for a myxoid liposarcoma. FDG-PET/CT has a high false-negative rate for detecting myxoid liposarcoma metastases and should be avoided as the primary screening modality [33-36].

Alveolar rhabdomyosarcoma also commonly metastasizes outside the lung. This tumor has an unusual pattern of spread, including in-transit, lymph node, bone marrow, pancreas, and bone metastases [37,38]. Although it has been suggested that metastatic disease surveillance should be different than routine sarcoma [39], no specific recommendations exist for alveolar rhabdomyosarcoma. Nodal metastases have been reported with extraosseous myxoid chondrosarcoma [40], but again, no specific recommendations exist for this tumor type.

**Variants 7 and 8: Surveillance for Local Osseous Tumor Recurrence With and Without Significant Hardware**

MRI is the mainstay for evaluation of soft-tissue or bone sarcoma diagnosis and recurrence [41-45]. MRI provides excellent delineation of the soft tissues and is an even more powerful tool in postoperative imaging due to advances in metal artifact suppression. MRI is useful both for surveillance and directed re-evaluation in cases with clinical concern [46]. There has been a relative paucity of research studies in the literature within the last 10 years regarding the effectiveness of MRI in this clinical situation, but this is likely due to its widespread routine clinical use. MRI has been shown to be efficacious in differentiating between recurrent tumor and post-treatment changes, although studies such as by Shapeero et al [47] were focused on other aspects of tumor research beyond MRI. The majority of the more recent literature focuses on accurate diagnosis of post-treatment changes versus tumor recurrence [42,45,48-52].

One reference suggests that patients treated with curettage and bone grafting can successfully have recurrences detected with gadolinium-enhanced MRI [53]. In addition to enhanced MRI, both radiographic and CT imaging of treated bone tumors are useful [54]. Imaging findings include enhancement of soft-tissue masses, osteolysis, cortical derangement, development of characteristic matrix, and alteration of the curetted cavity.

In addition to MRI, radiographic evaluation of the area of prior tumor is an important additional adjunct for the interpretation of the MRI examination.

In evaluating whether CT or MRI is more efficacious in follow-up of sarcomas, one should discount articles performed over a decade ago as MRI has dramatically improved over the years since the studies were performed. CT remains useful for imaging of patients who have contraindications to MR scanning and for evaluation of osseous changes, particularly when metal artifact cannot be overcome on MRI. With regard to CT imaging of the abdomen and pelvis for metastatic surveillance after Ewing sarcoma, this practice should not be routinely performed [55].

Metal artifact associated with allograft treatment of bone sarcomas has historically been a challenge to overcome for surveillance imaging of recurrent tumor and previously necessitated the use of radiographs or radionuclide imaging. However, advancements in metal suppression technique for both CT and MRI have made both of these modalities powerful tools for detection of recurrent tumor and complications [56-59]. Postoperative imaging recommendations that include references to MR or CT imaging in cases where there is no significant metal artifact [60] can be more broadly applied with implementation of metal artifact suppression techniques.
Extracorporeal irradiation and reimplantation of bone involved with tumor is a relatively uncommon treatment therapy. Surveillance for recurrent tumor in this treatment scenario has been effective using dynamic contrast-enhanced MRI [47].

There has been a significant amount of literature exploring the use of FDG-PET and FDG-PET/CT in evaluating recurrent soft-tissue and osseous sarcoma. Virtually all clinical studies today are done with FDG-PET/CT, which is reasonably expected and has been proven [61] to be a more powerful tool than FDG-PET alone. Thus, studies regarding the effectiveness of FDG-PET alone are not considered for this discussion.

FDG-PET/CT is a strong rival to MRI for local and distant tumor surveillance due to the anatomic data obtained from thin-slice CT through the entire body and functional tumor metabolism assessment from maximum standardized uptake value (SUV$_{\text{max}}$) measurements. FDG-PET/CT is highly sensitive and specific for detection of bone and soft-tissue sarcoma recurrence [62]. It also has higher diagnostic accuracy than contrast-enhanced CT alone [62]. FDG-PET/CT outperformed conventional imaging with MRI, CT, and bone scan in a series of 13 children with rhabdomyosarcoma, resulting in a change in lymph node staging, bone involvement, and treatment [63]. Potential limitations of the CT portion of a FDG-PET/CT study include lack of intravenous contrast and lack of breath-hold technique [64]. Bone lesions identified on FDG-PET are not always visible on CT [65]. Although FDG-PET/CT has a high positive predictive value when findings are concordant, the positive predictive value has been shown to markedly decrease when findings are discordant [66].

A study by Costelloe et al [67] showed that the SUV$_{\text{max}}$ obtained with FDG-PET/CT can predict prognosis in osteosarcoma. A high SUV$_{\text{max}}$ before chemotherapy correlated with worse progression-free survival. A high SUV$_{\text{max}}$ after chemotherapy correlated with both a worse progression-free survival and poor overall survival. A decrease in SUV$_{\text{max}}$ after chemotherapy correlated with >90% tumor necrosis and good overall and progression-free survival. Along these lines, the SUV$_{\text{max}}$ can be used to detect recurrence of metastatic lung lesions that have been treated with radiofrequency ablation [20].

Drawbacks of FDG-PET/CT relative to MRI include higher radiation exposure with subsequent cancer risk [68,69] and decreased availability of this technology.

Additional outcomes data for FDG-PET/CT are expected as a result of the National Oncologic PET Registry (www.cancerpetregistry.org). Future studies will likely expand on the use of additional radiotracers such as 18F-fluoride [70] and PET/MRI [71].

**Timing of Surveillance for Local Recurrence**

Local recurrence can be as low as 9%–12% at 5 and 10 years using multimodality therapy as well as limb-sparing surgery [9] and may be routinely as low as 10% in patients with high-grade sarcomas <5 cm at the time of diagnosis. Local recurrence ranged from 4.1% to 23.4% in several large studies [10,72-74]. Different studies have related local failure to tumor grade and type of resection. A multivariate analysis found histologic type and absence of wide resection to statistically impact local recurrence [74]. Sabolch et al [10] found that local recurrence was significantly impacted by having an intermediate/high grade tumor and having multifocally positive surgical margins. They also found that local recurrence predicted an increased chance of metastasis and worsened survival. The impact of a local recurrence on survival varies in the literature. Novais et al [73] also found that local recurrence and microscopically positive surgical margins correlated with worsened survival. In another study, long-term survival was influenced only by local control of tumor, and local relapse was related to surgical margins, radiation therapy, and histologic type [72]. Another study noted that patients with a positive surgical margin are 3.76 times more likely to have a local recurrence, but having a recurrence did not change survival [11]. Patients undergoing limb amputation for local control of tumor have been found to have a 3 times higher risk of mortality [75]. Failing to resect a core needle biopsy tract was not found to increase local recurrence (8.5%) in a study where all patients received adjuvant therapy, including radiation (97%) and chemotherapy (83%), and that used the literature as a comparison group [76].

Because of the different findings regarding the importance of local recurrence in survival, it seems reasonable to establish a suggested timing sequence for evaluating local recurrence, with the caveat that for marginal excision and intermediate- to high-grade tumor, more frequent follow-up may be efficacious. One retrospective analysis drawing on a review of 1500 patients from the Memorial Sloan-Kettering Cancer Center and the MD Anderson Cancer Center recommended follow-up of adult soft-tissue sarcomas [77] based on low and high risk of recurrence. Risk stratification was based on size of primary neoplasm (T1: low risk, <5 cm; T2: high risk, >5 cm).
For local recurrence in low-risk patients, the recommendation was for “cross-sectional imaging of choice” individualized for patient and location of primary tumor. The implication is that for extremity primaries, the clinical examination may obviate the need for routine cross-sectional imaging follow-up in the low-risk group. Cross-sectional imaging follow-up for less accessible areas (trunk or retroperitoneum) would be required at 3–4 month intervals for 2 years, 4–6 month intervals for 2 years, and yearly thereafter. Within the low-risk group, one could consider stopping surveillance after 5–10 years, although local recurrence has been documented at over 11 years after resection [78].

Within the high-risk group, the local recurrence rate was noticeably higher, and the analysis recommended cross-sectional imaging every 3 months for 2 years, every 4 months for the next 2 years, every 6 months for the fifth year, and then annually [77]. A study looking at soft-tissue sarcoma patients who were alive and without recurrence or metastasis at 5 years showed that the size and grade of tumor predicted adverse events [79]. Of those living patients, the late relapse rate was 6.3%, which led to 50% mortality. An analysis of high-grade soft-tissue sarcomas found that poor overall survival was associated with tumor size, particularly >8 cm, and the presence of metastasis before tumor resection [80]. Regarding particular tumor histologic types, synovial sarcomas have a propensity to metastasize after 5 years [81]. These data may necessitate a more tailored approach to follow-up of patients with bone or soft-tissue sarcoma, especially those with particular histologic primaries, large tumor size, presence of presurgical metastasis, and positive surgical margins.

Very few follow-up MRI protocols have been advocated. However, Vanel et al [52] suggest an algorithm for following soft-tissue tumors postoperatively. This algorithm starts with T2 imaging. If a mass is present on T2-weighted imaging, it should be followed by T1-weighted sequences with and without contrast. This procedure generally distinguishes hematoma and seroma from tumor or inflammation. If necessary, this procedure can be followed by dynamic enhanced imaging with subtraction postprocessing, which further helps differentiate tumors from inflammation. In this algorithm, if a region of high signal intensity is seen on T2-weighted imaging but there is no mass present, further evaluation with contrast imaging is not recommended. They state that there will be some exceptions to the above recommendations. Contrast may be particularly helpful when assessing for recurrence in the presence of postoperative hematoma [51] and assessing the acuity of bone metastases [82]. Based on these authors’ experience, they advocate delaying the postoperative baseline scan for at least 6–8 weeks to allow postoperative changes to subside.

**Variant 9: Soft-tissue tumors, without significant hardware present. Local recurrence surveillance. Follow-up examination 3–6 months after treatment or surgery**

As noted above, MRI is the mainstay to evaluate for recurrent soft-tissue tumors. FDG-PET/CT has emerged as a powerful tool for evaluating local recurrence, particularly in the face of suboptimal cross-sectional imaging because of large amounts of metal. FDG-PET/CT and its possible applications are addressed separately above. It has recently been suggested that surveillance imaging for recurrent soft-tissue sarcomas be done only in the setting where the primary tumor site is difficult to evaluate clinically [83].

Recurrence involving only the soft tissues can also be detected by ultrasound (US). No recent studies specifically advocate the use of US over MRI in follow-up for soft-tissue masses, although US is a cost-effective alternative in many cases. As with studies comparing MRI to CT, studies comparing US to MRI that are over a decade old should be discounted due to technologic advances. US may be particularly useful in the presence of extensive hardware, with a palpable clinical concern for recurrence or for surveillance of easily accessible operative sites. Color Doppler flow imaging can help differentiate recurrent tumor mass from fibrous tissue or other nonvascular tissue in the postoperative tumor site; this was shown to be helpful in the presence of hardware and if there is a baseline postoperative Doppler study [52].

**Summary of Recommendations**

- In patients with a musculoskeletal primary malignancy and either a high or low risk for metastatic disease, evaluation for pulmonary metastases should be performed using a CT scan of the chest without contrast. The baseline postoperative examination should occur within 3–6 months. Additional chest CT scans should be performed every 3–6 months for the first 10 years, although after 5 years, a decrease in frequency to every 6–12 months can be considered on an individual basis.

- Osseous metastatic disease from a musculoskeletal primary malignancy should be imaged only if symptomatic. Osseous metastatic disease screening utilizing MRI can be considered in patients with myxoid liposarcoma, as these patients have a disproportionately high rate of soft-tissue and bone metastases compared
with other musculoskeletal primary neoplasms. Whole-body FDG-PET/CT has a high false-negative rate for myxoid liposarcoma metastases and should not be considered a first-line screening tool for this tumor type.

- Baseline imaging of the tumor area should be performed 3–6 months postoperatively. Follow-up imaging should occur every 3–6 months for 10 years. After 5 years, a decrease in frequency to every 12 months can be considered on an individual basis. Additional imaging should occur earlier if the patient becomes symptomatic.

- For surveillance of osseous tumor local recurrence without significant hardware present, both radiographs and an MRI with or without contrast of the area of interest are indicated. If significant hardware is present, radiographs should be obtained, and an MRI can be attempted using metal suppression techniques. Whole-body FDG-PET/CT can be a useful problem-solving tool if study findings are equivocal.

- For evaluation of soft-tissue tumor local recurrence, MRI of the area of interest with or without contrast is recommended. Whole-body FDG-PET/CT is useful as a problem-solving tool if MRI is equivocal.

Future Research

FDG-PET/CT continues to be an area of robust growth and research, with current evidence supporting its use as a problem-solving tool in equivocal cases of local or distant recurrence detected on MRI or CT. In addition, it may have high use in evaluating tumor recurrence in patients with orthopedic hardware that limits accurate use of MRI or CT. Low sensitivity for low-grade neoplasms and insensitivity for bony metastases of osteosarcoma are exceptions that need to be considered by the interpreting and ordering physician. Routine use of FDG-PET/CT beyond a problem-solving role has not been widely advocated in the literature, though anecdotal experiences are increasing rapidly. The panel feels that this emerging technology deserves recognition as a problem-solving tool and as a primary diagnostic tool for metastatic lesion detection and surveillance, at least in high-grade musculoskeletal tumors. Furthermore, the results of current studies and recent experience warrant a systematic prospective multicenter evaluation of its clinical value in diagnosis, staging, response to therapy, and detecting recurrence and metastatic disease of bone and soft-tissue sarcomas. Any such study must include its influence on outcome as well as a cost-benefit analysis. The same might be said for much of the other imaging recommended in this document. The desired evidence-based data are difficult to obtain for bone and soft-tissue sarcomas. We therefore strive for a logical consensus that allows for optimizing patient and cost benefit. The result must allow for some nonuniformity, since clinical judgment remains of paramount importance in these cases.

Summary of Evidence

Of the 83 references cited in the *ACR Appropriateness Criteria® Follow-up of Malignant or Aggressive Musculoskeletal Tumors* document, 63 are categorized as diagnostic references including 7 good quality studies and 16 quality studies that may have design limitations. Additionally, 20 references are categorized as therapeutic references including 14 good quality studies. There are 46 references that may not be useful as primary evidence.

The 83 references cited in the *ACR Appropriateness Criteria® Follow-up of Malignant or Aggressive Musculoskeletal Tumors* document were published from 2003-2014.

While there are references that report on studies with design limitations, 21 good quality studies provide good evidence.

Relative Radiation Level Information

Potential adverse health effects associated with radiation exposure are an important factor to consider when selecting the appropriate imaging procedure. Because there is a wide range of radiation exposures associated with different diagnostic procedures, a relative radiation level (RRL) indication has been included for each imaging examination. The RRLs are based on effective dose, which is a radiation dose quantity that is used to estimate population total radiation risk associated with an imaging procedure. Patients in the pediatric age group are at inherently higher risk from exposure, both because of organ sensitivity and longer life expectancy (relevant to the long latency that appears to accompany radiation exposure). For these reasons, the RRL dose estimate ranges for pediatric examinations are lower as compared to those specified for adults (see Table below). Additional information regarding radiation dose assessment for imaging examinations can be found in the ACR Appropriateness Criteria® *Radiation Dose Assessment Introduction* document.
**Relative Radiation Level Designations**

<table>
<thead>
<tr>
<th>Relative Radiation Level*</th>
<th>Adult Effective Dose Estimate Range</th>
<th>Pediatric Effective Dose Estimate Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>O</td>
<td>0 mSv</td>
<td>0 mSv</td>
</tr>
<tr>
<td>☢</td>
<td>&lt;0.1 mSv</td>
<td>&lt;0.03 mSv</td>
</tr>
<tr>
<td>☢☢</td>
<td>0.1-1 mSv</td>
<td>0.03-0.3 mSv</td>
</tr>
<tr>
<td>☢☢☢</td>
<td>1-10 mSv</td>
<td>0.3-3 mSv</td>
</tr>
<tr>
<td>☢☢☢☢</td>
<td>10-30 mSv</td>
<td>3-10 mSv</td>
</tr>
<tr>
<td>☢☢☢☢☢</td>
<td>30-100 mSv</td>
<td>10-30 mSv</td>
</tr>
</tbody>
</table>

*RRL assignments for some of the examinations cannot be made, because the actual patient doses in these procedures vary as a function of a number of factors (eg, region of the body exposed to ionizing radiation, the imaging guidance that is used). The RRLs for these examinations are designated as “Varies”.

**Supporting Documents**

For additional information on the Appropriateness Criteria methodology and other supporting documents go to [www.acr.org/ac](http://www.acr.org/ac).

**References**


17. Miller BJ, Carmody Soni EE, Reith JD, Gibbs CP, Scarborough MT. CT scans for pulmonary surveillance may be overused in lower-grade sarcoma. Iowa Orthop J. 2012;32:28-34.
64. Iagaru A, Chawla S, Menendez L, Conti PS. 18F-FDG PET and PET/CT for detection of pulmonary metastases from musculoskeletal sarcomas. Nucl Med Commun. 2006;27(10):795-802.

The ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient’s clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those examinations generally used for evaluation of the patient’s condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.